Chiesi Group is an international research-focused pharmaceuticals and healthcare group with over 85 years’ experience with more than 6,000 employees worldwide and a commercial presence in 100 countries. To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). Chiesi Group has direct Affiliates in 30 countries worldwide plus 68 countries where Chiesi is present with a network of partners. Chiesi became a certified B Corp in 2019 and a Benefit Corporation, thus choosing to adopt a new legal status under Italian, US and French law. With the B Corp Certification, Chiesi reinforces its mission to improve the quality of human life, by acting responsibly towards the society and the environment and by adopting a unified standard of measurement within the Group.